SCHEMBL607256

SCHEMBL607256

Cn1c(=O)oc(=O)c2cc(Cl)ccc21

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.44
TSHR P16473 1/20 0.42
KDM4E B2RXH2 3/20 0.42
HCRTR1 O43613 1/20 0.42
MAPT P10636 1/20 0.42
CASP1 P29466 1/20 0.42
CASP7 P55210 1/20 0.42
NOS3 P29474 1/20 0.40
NOS1 P29475 1/20 0.40
NOS2 P35228 1/20 0.40
USP2 O75604 1/20 0.39
LMNA P02545 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
GABRA1 P14867 3/20 0.39
GABRG2 P18507 3/20 0.39
GABRB3 P28472 3/20 0.39
GABRA5 P31644 3/20 0.39
BAZ2B Q9UIF8 1/20 0.39
MEN1 O00255 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29811258 1.00 PKM (0.44) PKMTSHRKDM4EHCRTR1MAPT
SCHEMBL10654664 0.86 MAT2A (0.48) PKMTSHRKDM4ENOS3NOS1
SCHEMBL5525919 0.81 KDM4E (0.45) PKMTSHRKDM4EMAPTUSP2
SCHEMBL29811263 0.81 KDM4E (0.45) PKMTSHRKDM4EMAPTUSP2
SCHEMBL4822294 0.79 ATM (0.45) PKMKDM4EHCRTR1LMNAMEN1
SCHEMBL22239410 0.79 PDE2A (0.46) PKMNPSR1ALDH1A1HPGD
SCHEMBL29811388 0.79 ATM (0.45) PKMKDM4EHCRTR1LMNAMEN1
SCHEMBL2384145 0.79 ESR2 (0.41) TSHRMAPTMEN1MAPK1KMT2A
SCHEMBL29811590 0.79 ALDH1A1 (0.37) PKMTSHRKDM4ELMNAMEN1
SCHEMBL29811309 0.79 ESR2 (0.41) TSHRMAPTMEN1MAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009226-A1 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2012-01-12 US claimed
EP-2376456-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF Actavis Group Ptc Ehf (IS) 2011-10-19 EP claimed
WO-2010070449-A2 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF ACTAVIS GROUP PTC EHF (IS) 2010-06-24 WO claimed
US-20240140949-A1 ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) 2024-05-02 US disclosed
WO-2022177305-A1 ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID 서울대학교 산학협력단 2022-08-25 WO disclosed
US-20190345137-A1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS GALAPAGOS NV (BE) 2019-11-14 US disclosed
US-20190345137-A1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS GALAPAGOS NV (BE) 2019-11-14 US disclosed
US-10208020-B2 Substituted amino triazoles useful as human chitinase inhibitors Oncoarendi Therapeutics S.A. (PL) 2019-02-19 US disclosed
US-10208020-B2 Substituted amino triazoles useful as human chitinase inhibitors Oncoarendi Therapeutics S.A. (PL) 2019-02-19 US disclosed
EP-3344616-B1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS ONCOARENDI THERAPEUTICS SA (PL) 2019-01-09 EP disclosed
EP-3344616-B1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS ONCOARENDI THERAPEUTICS SA (PL) 2019-01-09 EP disclosed
EP-0015065-B1 PYRAZOLO (5,1-B) QUINAZOLIN-9(4H)-ONE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM WARNER-LAMBERT COMPANY (US) 1983-12-28 EP disclosed
US-4284768-A 1,2-Dihydro-4-amino-2-oxo-3-quinoline-carboxylic acid derivatives AMERICAN HOME PRODUCTS CORPORATION (US) 1981-08-18 US disclosed
US-4266050-A DIURETICS AMERICAN HOME PRODUCTS CORPORATION (US) 1981-05-05 US disclosed
US-4261997-A 4-Alkyl-pyrazolo[5,1-b]-quinazolin-9(4H)-ones and anti-allergic compositions containing them WARNER-LAMBERT COMPANY (US) 1981-04-14 US disclosed
EP-0015065-A1 Pyrazolo (5,1-b) quinazolin-9(4H)-one derivatives, process for their preparation and pharmaceutical compositions containing them WARNER-LAMBERT COMPANY (US) 1980-09-03 EP disclosed
US-4104274-A 1-Substituted-2-(2-pyridinyl)ethanone N-oxides WARNER-LAMBERT COMPANY (US) 1978-08-01 US disclosed
US-4076720-A 1-Substituted-2-(2-pyridinyl)ethanone N-oxides WARNER-LAMBERT COMPANY (US) 1978-02-28 US disclosed
US-4056619-A 1-Substituted-2-(2-pyridinyl)ethanone N-oxides WARNER-LAMBERT COMPANY (US) 1977-11-01 US disclosed
US-3947408-A ANTIANXIETY AGENTS AMERICAN CYANAMID COMPANY (US) 1976-03-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190345137-A1 SUBSTITUTED AMINO TRIAZOLES USEFUL AS HUMAN CHITINASE INHIBITORS CHIA, CHIT1, AADAC PKM 2017/4885TSHR 1649/4885KDM4E 2790/4885
US-20120009226-A1 HIGHLY PURE LAQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF TLR7, MYD88, PDE7A PKM 3000/4885TSHR 4643/4885KDM4E 422/4885
US-10208020-B2 Substituted amino triazoles useful as human chitinase inhibitors CHIA, CHIT1, AADAC PKM 2017/4885TSHR 1649/4885KDM4E 2790/4885
US-20240140949-A1 ANTI-CANCER PHARMACEUTICAL COMPOSITION FOR TARGETING HEAT SHOCK PROTEIN 70, CONTAINING INDOLOQUINAZOLIDINE ALKALOID HSPH1, HSP90AB2P, HSPBP1 PKM 3241/4885TSHR 4769/4885KDM4E 3757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.